Senior Vice President Clinical Pharmacology, Pharmacometrics & Bioanalysis
Bristol Myers Squibb
Akintunde (Tunde) Bello is Senior Vice President and Head of Clinical Pharmacology, Pharmacometrics, and Bioanalysis at BMS supporting the therapeutic areas of Oncology, Hematology, Cell Therapy, Immunology, cardiovascular and Neurology. Tunde has more than 25 years of experience in preclinical and clinical drug development. He started his career at Rhone Poulenc Rorer in the UK and moved to the US to join BMS in 1998 where he spent 5 years working on the development of anti-infective and oncology therapeutics. Following 11 years at Pfizer, as a clinical pharmacology group leader, Tunde rejoined BMS in 2015 to head up clinical pharmacology and pharmacometrics for oncology.
In his current role, Tunde also has quantitative systems pharmacology, physiologically based PK, clinical pharmacology analysis & reporting, and clinical pharmacology data sciences functions within his organization. Over the course of his career, Tunde has played key roles in the development, approval, and life cycle management of 16 marketed drugs in the oncology, pain management, inflammation, and infectious disease therapeutic areas. He oversaw the clinical pharmacology teams that supported the development and approval of multiple sBLAs for nivolumab and ipilimumab, as well as the BLA for elotuzumab. At Pfizer, Tunde managed the clinical pharmacology team that supported the development of crizotinib (xalkori).
Tunde has a BSc in Medical Laboratory Sciences (Biomedical Sciences), Portsmouth University (UK), a MSc in Instrumentation and Analytical Sciences, the University of Manchester Institute of Science and Technology (UK) and a PhD in Pharmaceutical Sciences from King’s College, University of London (UK).
Tunde has authored and co-authored more than 70 peer reviewed abstracts and journal manuscripts, he is a member of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), the International Society of Pharmacometrics (ISoP), the American Association of Pharmaceutical Scientists (AAPS) and the American Society of Clinical Oncology (ASCO).
Disclosure(s): Bristol Myers Squibb: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Friday, March 29, 2024
1:30 PM – 2:30 PM MDT